Merck announced the withdrawal of the U.S. indication for Keytruda for the treatment of patients with metastatic small cell lung cancer
Merck announced the company is voluntarily withdrawing the U.S. indication for Keytruda (pembrolizumab) for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression… read more.
